Loading...
CD34+ hematopoietic progenitor cell dose as a predictor of engraftment and survival in multiple myeloma patients undergoing autologous stem cell transplantation
BACKGROUND/AIM: High-dose melphalan and autologous hematopoietic stem cell transplantation (AHSCT) is the standard treatment strategy for multiple myeloma (MM) patients who are eligible for it. The recommended dose of CD34+ hematopoietic progenitor cells (HPCs) for adequate engraftment is above 2 ×...
Na minha lista:
| Udgivet i: | Turk J Med Sci |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
The Scientific and Technological Research Council of Turkey
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7775700/ https://ncbi.nlm.nih.gov/pubmed/32512672 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3906/sag-2001-173 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|